Celcuity
Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, with its lead candidate, gedatolisib, aimed at inhibiting PI3K and mTOR pathways.
Company Overview
Celcuity is a clinical stage biotechnology company focused on discovering previously undetectable cancer drivers and developing new targeted therapies to treat cancer patients. The company employs a third-generation cellular analysis platform to unravel complex oncogenic activities that molecular tests cannot detect. Through comparative analyses of different drugs using live patient tumor cells, Celcuity reveals opportunities to develop first-in-class drugs.
Lead Candidate Gedatolisib
Celcuity's lead candidate is gedatolisib, a dual PI3K – mTOR inhibitor. Gedatolisib is currently in clinical trials for breast cancer and prostate cancer. The dual inhibition mechanism targets critical pathways involved in cancer cell growth and survival, aiming to provide a more effective treatment option for patients.
Clinical Trials
Celcuity conducts clinical trials to evaluate the efficacy and safety of their investigational drugs. The primary focus is on breast cancer and prostate cancer. These trials involve the use of gedatolisib and other drug candidates, employing live patient tumor cells for comparative analyses to identify the most promising therapeutic approaches.
Expanded Access Program
Celcuity offers an Expanded Access Program for patients who initially received investigational medicine as participants in a clinical trial that is no longer open. This program allows patients continued access to the investigational treatment, ensuring they can benefit from the therapeutic advancements made during clinical research.